The earnings call highlighted significant advancements in the efficacy of vormatrigine, strong execution of clinical trials, and a robust financial position. However, challenges remain in managing discontinuation rates and background therapy interactions.

Company Guidance

During the Praxis Precision Medicine's conference call, significant guidance was provided on the company's ongoing and future clinical developments. Praxis highlighted the promising results from their RADIANT study of vormatrigine, which showed a median seizure reduction of over 56%, with 60% of patients achieving at least a 50% reduction in seizures. Notably, 22% of patients were seizure-free during the second month of treatment. The company discussed its robust pipeline, featuring four late-stage assets and five expected clinical readouts within the next year. They emphasized their solid financial position, with a cash runway extending into 2028, supporting their ambitious clinical agenda. Looking ahead, Praxis plans to initiate the POWER2 study, which will test vormatrigine doses of 20, 30, and 40 milligrams, and the POWER3 study, aiming to establish vormatrigine as a stand-alone therapy. The company also announced that the full RADIANT study results would be further detailed at upcoming epilepsy conferences.

Vormatrigine Best-in-Disease Efficacy

The RADIANT study showed vormatrigine delivered a median seizure reduction of over 56%, with 60% of patients achieving at least a 50% reduction in seizures. Over 22% of patients were completely seizure-free during the second month of treatment.

Strong Patient Recruitment and Study Execution

Praxis successfully exceeded its enrollment target for the RADIANT study, recruiting a larger group of patients than initially planned, demonstrating effective recruitment capabilities.

Positive Mood Impact

Patients in the RADIANT study reported positive impacts on mood, leading to the inclusion of depression and mood endpoints in the POWER2 study design.

Strong Financial Position

Praxis' cash runway extends into 2028, supporting its ambitious clinical agenda.

Praxis Precision Medicines (PRAX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PRAX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-3.39 / -	-2.75	―	―	―
Aug 04, 2025	2025 (Q2)	-3.25 / -3.31	-1.74	-90.23% (-1.57)
May 02, 2025	2025 (Q1)	-3.21 / -3.29	-2.84	-15.85% (-0.45)	―	―
Feb 28, 2025	2024 (Q4)	-2.85 / -2.94	-2.97	1.01% (+0.03)	―	―
Nov 06, 2024	2024 (Q3)	-1.99 / -2.75	-2.7	-1.85% (-0.05)	―
Aug 13, 2024	2024 (Q2)	-2.31 / -1.74	-7.35	76.33% (+5.61)	―
May 12, 2024	2024 (Q1)	-2.08 / -2.84	-10.65	73.33% (+7.81)	―	―
Mar 05, 2024	2023 (Q4)	-3.05 / -2.97	-13.05	77.24% (+10.08)	―	―
Nov 07, 2023	2023 (Q3)	-3.90 / -2.70	-14.4	81.25% (+11.70)	―	―
Aug 09, 2023	2023 (Q2)	-9.84 / -7.35	-19.8	62.88% (+12.45)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PRAX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$54.09	$51.09	-5.55%
May 02, 2025	$38.06	$40.24	+5.73%
Feb 28, 2025	$65.03	$38.60	-40.64%
Nov 06, 2024	$72.73	$71.87	-1.18%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Praxis Precision Medicines (PRAX) report earnings?

Praxis Precision Medicines (PRAX) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).

What is Praxis Precision Medicines (PRAX) earnings time?

Praxis Precision Medicines (PRAX) earnings time is at Nov 05, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PRAX EPS forecast?

PRAX EPS forecast for the fiscal quarter 2025 (Q3) is -3.39.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing